This article summarizes the findings, conclusions,
and recommendations of an evidence-based guideline
regarding periprocedural management of patients
with a history of ischemic cerebrovascular disease
receiving AC or AP agents. The full text of the guideline
is available as a data supplement on the Neurology®
Web site at www.neurology.org. Four questions are
addressed: